MedTrace Logo

To Compare the Efficacy and Safety of FK506 vs IVC in the Treatment of Class III-IV LN

NCT00302549 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2010-05-27

No results posted yet for this study

Summary

1. To compare the efficacy of FK506 vs intravenous cyclophosphamide pulses in the treatment of class III-IV LN.
2. To compare the safety and tolerability of FK506 vs intravenous cyclophosphamide pulses in the treatment of class III-IV LN.
3. To explore the dosing of FK506 and its effective range of blood concentration.

Conditions

Interventions

DRUG

FK506

FK506,0.1mg/kg/d

Sponsors & Collaborators

  • Sun Yat-sen University

    collaborator OTHER

  • Nanjing University School of Medicine

    lead OTHER

Principal Investigators

  • Lei-shi Li, M.D. · Research Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-05-31
Primary Completion
2005-05-31
Completion
2006-02-28

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00302549 on ClinicalTrials.gov